Oncolytic virotherapy can reprogram an immunosuppressive TME but can also significantly increase the expression of PD-L1 on breast cancer cells, which leads to immune escape after oncolytic virotherapy.22 The combination of an OV and anti-PD-1 can solve this problem perfectly. Here, PDCD1 is linked to breast carcinoma.